AR044706A2 - Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp - Google Patents

Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Info

Publication number
AR044706A2
AR044706A2 ARP040102071A ARP040102071A AR044706A2 AR 044706 A2 AR044706 A2 AR 044706A2 AR P040102071 A ARP040102071 A AR P040102071A AR P040102071 A ARP040102071 A AR P040102071A AR 044706 A2 AR044706 A2 AR 044706A2
Authority
AR
Argentina
Prior art keywords
aminoquinolins
procedures
prepare
cetp inhibitors
compound
Prior art date
Application number
ARP040102071A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR044706A2 publication Critical patent/AR044706A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un procedimiento para preparar un compuesto de fórmula (1), que comprende combinar el compuesto de fórmula (2), con un haluro de 3,5-bis(trifluorometil)bencilo en presencia de una base.
ARP040102071A 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp AR044706A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
AR044706A2 true AR044706A2 (es) 2005-09-21

Family

ID=23103272

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020101576A AR036331A1 (es) 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP020101576A AR036331A1 (es) 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion

Country Status (24)

Country Link
US (3) US6689897B2 (es)
EP (2) EP1425270B1 (es)
JP (2) JP3924251B2 (es)
KR (2) KR100639745B1 (es)
CN (3) CN1297541C (es)
AR (3) AR036331A1 (es)
AT (2) ATE321755T1 (es)
AU (1) AU2002253448B2 (es)
BR (2) BR0209238A (es)
CA (2) CA2445693A1 (es)
CZ (2) CZ20032900A3 (es)
DE (2) DE60210265T2 (es)
DK (2) DK1425270T3 (es)
ES (2) ES2259080T3 (es)
HU (2) HUP0304039A3 (es)
IL (2) IL157544A0 (es)
MX (2) MXPA03009936A (es)
PL (2) PL366700A1 (es)
PT (1) PT1425270E (es)
RU (2) RU2265010C2 (es)
TW (1) TWI250974B (es)
WO (2) WO2002088085A2 (es)
YU (2) YU84303A (es)
ZA (2) ZA200306599B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
KR20050055747A (ko) 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료용의 ｐｇｄ2 수용체 길항제
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
WO2004074255A2 (en) * 2003-02-18 2004-09-02 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
CA2515789A1 (en) * 2003-03-17 2004-09-30 Kaneka Corporation Method for producing(r)-3-[4-(trifluoromethyl)phenylamino]-pentanoic acid amide derivative
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
AU2004282101A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
EP1680099B1 (en) * 2003-11-07 2009-04-15 JJ Pharma, Inc. Hdl-boosting combination therapy complexes
MXPA06011540A (es) * 2004-04-07 2007-01-26 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
BRPI0512523A (pt) * 2004-06-24 2008-03-11 Lilly Co Eli composto ou um sal, enanciÈmero, racemato, diastereÈmero ou mistura de diastereÈmeros farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
JP2008543726A (ja) 2005-02-24 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
BRPI0611838A2 (pt) * 2005-06-20 2012-08-28 Astrazeneca Ab processo para a preparação de um composto
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP2697207B1 (en) 2011-04-12 2016-12-14 Chong Kun Dang Pharmaceutical Corp. 3-(2-aryl-cycloalkenylmethyl)-oxazolidin-2-one derivatives as cholesterol ester transfer protein (cetp) inhibitors
SG10201605304VA (en) 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
PL2943474T3 (pl) 2013-01-31 2017-12-29 Chong Kun Dang Pharmaceutical Corp. Związki stanowiące pochodne cycloheksenu podstawionego biarylem lub heterocyklicznym biarylem jako inhibitory cetp
HK1221073A1 (zh) * 2013-11-11 2017-05-19 Lonza Ltd 利用路易斯酸制备第13族元素的氰基化合物的方法
SMT202200385T1 (it) * 2014-08-12 2022-11-18 Newamsterdam Pharma B V Processo per la preparazione di composti intermedi sintetici per la preparazione di derivati di tetraidrochinolina
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205037B (es) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
DE69935933T2 (de) 1998-07-10 2008-01-10 Massachusetts Institute Of Technology, Cambridge Liganden für Metalle und verbesserte Metall-katalysierte Verfahren, die darauf basieren
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.

Also Published As

Publication number Publication date
IL157544A0 (en) 2004-03-28
RU2265010C2 (ru) 2005-11-27
CN1267411C (zh) 2006-08-02
YU84403A (sh) 2006-08-17
PL366584A1 (en) 2005-02-07
US20030073843A1 (en) 2003-04-17
DK1383734T3 (da) 2006-05-15
CN1680292A (zh) 2005-10-12
US20030216576A1 (en) 2003-11-20
HUP0304041A2 (hu) 2004-04-28
US6600045B2 (en) 2003-07-29
HUP0304041A3 (en) 2005-08-29
WO2002088069A2 (en) 2002-11-07
YU84303A (sh) 2006-05-25
CN1505609A (zh) 2004-06-16
WO2002088069A9 (en) 2003-12-04
ATE321755T1 (de) 2006-04-15
ZA200306600B (en) 2004-08-25
AR035963A1 (es) 2004-07-28
JP2004531541A (ja) 2004-10-14
US6706881B2 (en) 2004-03-16
CA2445693A1 (en) 2002-11-07
EP1425270A2 (en) 2004-06-09
CZ20032900A3 (cs) 2004-06-16
TWI250974B (en) 2006-03-11
CA2445623A1 (en) 2002-11-07
US6689897B2 (en) 2004-02-10
CN100357265C (zh) 2007-12-26
ES2256461T3 (es) 2006-07-16
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
DE60210265D1 (de) 2006-05-18
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
JP3924250B2 (ja) 2007-06-06
ZA200306599B (en) 2004-10-22
HK1062294A1 (en) 2004-10-29
WO2002088085A3 (en) 2004-03-25
EP1383734B1 (en) 2006-02-01
CZ20032898A3 (cs) 2004-07-14
MXPA03009936A (es) 2004-01-29
WO2002088069A3 (en) 2003-02-20
RU2003131870A (ru) 2005-01-27
JP3924251B2 (ja) 2007-06-06
WO2002088085A2 (en) 2002-11-07
HUP0304039A2 (hu) 2004-03-29
KR20040015200A (ko) 2004-02-18
AU2002253448B2 (en) 2007-07-05
ATE316957T1 (de) 2006-02-15
PT1425270E (pt) 2006-07-31
ES2259080T3 (es) 2006-09-16
HUP0304039A3 (en) 2005-10-28
RU2003131871A (ru) 2005-04-10
DK1425270T3 (da) 2006-07-03
DE60210265T2 (de) 2006-10-12
JP2004527556A (ja) 2004-09-09
DE60209004T2 (de) 2006-09-28
CN1297541C (zh) 2007-01-31
PL366700A1 (en) 2005-02-07
MXPA03009935A (es) 2004-01-29
EP1425270B1 (en) 2006-03-29
KR100591998B1 (ko) 2006-06-22
CN1529696A (zh) 2004-09-15
BR0209291A (pt) 2004-07-13
HU225777B1 (en) 2007-08-28
EP1383734A2 (en) 2004-01-28
DE60209004D1 (de) 2006-04-13
IL157546A0 (en) 2004-03-28
KR100639745B1 (ko) 2006-10-30
US20020177716A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
AR044706A2 (es) Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp
YU5503A (sh) Nesteroidni supresori zapaljenja
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
EA200500017A1 (ru) Новые соединения
TR200001876T2 (tr) HIV proteaz inhibitörünün bisülfat tuzu.
DK0931788T3 (da) Metalloproteasehæmmere
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
AR030893A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gabaa para el tratamiento de trastornos cognitivos
EA200201057A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
ES2159488B1 (es) Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.
MXPA04009476A (es) Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
SE0103710D0 (sv) Compounds
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
DK1349578T3 (da) Kombinationspræparat indeholdende en biguanin (metformin) og arginin
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
BR0007922A (pt) Compostos calcilìticos
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
AR044175A1 (es) Compuestos de cefemo
IT1320107B1 (it) Procedimento per la preparazione di derivati tassanici.
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal